Dr. Debra L. Friedman
Claim this profileVanderbilt University/Ingram Cancer Center
Area of expertise
Cancer
Debra L. Friedman has run 6 trials for Cancer. Some of their research focus areas include:
Burkitt Lymphoma
Debra L. Friedman has run 4 trials for Burkitt Lymphoma. Some of their research focus areas include:
Affiliated Hospitals
Vanderbilt University/Ingram Cancer Center
Vanderbilt-Ingram Cancer Center
Clinical Trials Debra L. Friedman is currently running
Inotuzumab Ozogamicin
for Acute Lymphoblastic Leukemia
This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy for patients with High-Risk B-cell Acute Lymphoblastic Leukemia (B-ALL) improves outcomes. This trial also studies the outcomes of patients with mixed phenotype acute leukemia (MPAL), and B-lymphoblastic lymphoma (B-LLy) when treated with ALL therapy without inotuzumab ozogamicin. Inotuzumab ozogamicin is a monoclonal antibody, called inotuzumab, linked to a type of chemotherapy called calicheamicin. Inotuzumab attaches to cancer cells in a targeted way and delivers calicheamicin to kill them. Other drugs used in the chemotherapy regimen, such as cyclophosphamide, cytarabine, dexamethasone, doxorubicin, daunorubicin, methotrexate, leucovorin, mercaptopurine, prednisone, thioguanine, vincristine, and pegaspargase or calaspargase pegol work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial will also study the outcomes of patients with mixed phenotype acute leukemia (MPAL) and disseminated B lymphoblastic lymphoma (B-LLy) when treated with high-risk ALL chemotherapy. The overall goal of this study is to understand if adding inotuzumab ozogamicin to standard of care chemotherapy maintains or improves outcomes in High Risk B-cell Acute Lymphoblastic Leukemia (HR B-ALL). The first part of the study includes the first two phases of therapy: Induction and Consolidation. This part will collect information on the leukemia, as well as the effects of the initial treatment, to classify patients into post-consolidation treatment groups. On the second part of this study, patients with HR B-ALL will receive the remainder of the chemotherapy cycles (interim maintenance I, delayed intensification, interim maintenance II, maintenance), with some patients randomized to receive inotuzumab. The patients that receive inotuzumab will not receive part of delayed intensification. Other aims of this study include investigating whether treating both males and females with the same duration of chemotherapy maintains outcomes for males who have previously been treated for an additional year compared to girls, as well as to evaluate the best ways to help patients adhere to oral chemotherapy regimens. Finally, this study will be the first to track the outcomes of subjects with disseminated B-cell Lymphoblastic Leukemia (B-LLy) or Mixed Phenotype Acute Leukemia (MPAL) when treated with B-ALL chemotherapy.
Recruiting
2 awards
Phase 3
Health Study After Leukemia Treatment
for People With Down Syndrome
This study attempts to learn more about the health of persons with Down syndrome after treatment for acute leukemia. Children with Down syndrome are at increased risk for side effects during treatment for acute leukemia, but it is unclear of their risk for long-term effects of cancer treatment. By learning more about the factors that may contribute to chronic health conditions and long-term effects after treatment for leukemia in persons with Down syndrome, clinical practice guidelines for survivorship care can be developed to help improve their quality-of-life.
Recruiting
1 award
N/A
10 criteria
More about Debra L. Friedman
Clinical Trial Related
6 years of experience running clinical trials · Led 16 trials as a Principal Investigator · 7 Active Clinical Trials
Treatments Debra L. Friedman has experience with
- Questionnaire Administration
- Nivolumab
- Daunorubicin Hydrochloride
- Thioguanine
- Quality-of-Life Assessment
- Cytology Specimen Collection Procedure
Breakdown of trials Debra L. Friedman has run
Cancer
Burkitt Lymphoma
Hodgkin's Lymphoma
Leukemia
Central Nervous System Hodgkin Lymphoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Debra L. Friedman specialize in?
Debra L. Friedman focuses on Cancer and Burkitt Lymphoma. In particular, much of their work with Cancer has involved Stage I patients, or patients who are Stage II.
Is Debra L. Friedman currently recruiting for clinical trials?
Yes, Debra L. Friedman is currently recruiting for 7 clinical trials in Nashville Tennessee. If you're interested in participating, you should apply.
Are there any treatments that Debra L. Friedman has studied deeply?
Yes, Debra L. Friedman has studied treatments such as Questionnaire Administration, Nivolumab, Daunorubicin Hydrochloride.
What is the best way to schedule an appointment with Debra L. Friedman?
Apply for one of the trials that Debra L. Friedman is conducting.
What is the office address of Debra L. Friedman?
The office of Debra L. Friedman is located at: Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee 37203 United States. This is the address for their practice at the Vanderbilt University/Ingram Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.